# NewBiologix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/newbiologix

- Industry: Biotechnology
- Headquarters: Lausanne, Switzerland
- Website: www.newbiologix.com
- Total disclosed funding: $50M
- Latest round: Series A (May 11, 2023)
- Investors on record: 1

## About

Based in Lausanne, Switzerland, and founded in 2022 by CEO Igor Fish and Senior Vice President Nicolas Mermod, NewBiologix SA operates as a developer of a DNA integration technology for cell line creation for gene and cell treatments. In May 2023, NewBiologix raised USD 50 million in Series A funding from Recipharm Venture Fund and the company's management.

NewBiologix SA developed advanced technologies and therapies to improve the field of gene therapy and cell therapy. The company offers technology for gene therapies which is stably engineered HEK that have integrated all genes necessary for rAAV production. In addition, the firm provides Cell-based therapies for improving treatment against the disease, targeted delivery, proliferation, and differentiation into specific body locations. NewBiologix SA provides next-generation sequencing (NGS) which is used to develop a bioinformatics platform that will help cell line engineering through different NGS-based technologies involving short reads, long reads, and optical mapping allowing for exceptionally in-depth datasets composed of a high-coverage sequence assembly.

## Funding rounds

- Series A, May 11, 2023, $50M — Recipharm Venture Fund

## Investors

- Recipharm Venture Fund (https://capitalatlas.ai/funds/recipharm-venture-fund) — Series A